However, although PD-L1 blockage treatment can improve the survival of Group 3 medulloblastoma in animal models (Pham et al., 2016), several studies indicated an absence of PD-L1 expression in medulloblastomas and suggested a limited value of immunotherapy with PD1/PD-L1 inhibitor (Majzner et al., 2017; Vermeulen et al., 2017), while others suggested that PD-L1 expression in medulloblastomas might be associated with infiltrating CD8+ T cells, and relatively high PD-L1 expression can be seen in some SHH and WNT cases (Bockmayr et al., 2018; Murata et al., 2018). The gene discussed is CD8A; the disease is medulloblastoma.